Retrospective Study on the Use of Immunotherapy in Patients With MSI-H Metastatic Colorectal Cancer

计划入组 100 人 · 首次发布于 2020 年 11 月 2 日

A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC)

计划入组 88 人 · 首次发布于 2026 年 9 月 8 日

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

计划入组 839 人 · 首次发布于 2019 年 7 月 5 日

Colorectal cancer vaccine (Oryx)

Oncolipin-IT Colorectal Cancer

anti-EGFR CAR T-cell therapy

Austrian Breast & Colorectal Cancer Study Group

Austria

H LEE MOFFITT CANCER CENTER

United States

H LEE MOFFITT CANCER CENTER AND RESEARCH

United States

Nouscom's NOUS-209 Shows Promise in Anti-PD-1 Resistant MSI-H Colorectal Cancer

EMA Recommends Nivolumab and Ipilimumab Combination for dMMR/MSI-H Metastatic Colorectal Cancer

Bristol Myers Squibb's OPDIVO Plus YERVOY Receives Positive Reimbursement Recommendation for MSI-H/dMMR Colorectal Cancer in Canada